Chloroquine hype is derailing the search for coronavirus treatments.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

16 citing papers in PubMed.

1. An Update on SARS-CoV-2 Clinical Trial Results-What We Can Learn for the Next Pandemic.International journal of molecular sciences · 2023
   Review
2. The Fragility of Scientific Rigour and Integrity in "Sped up Science": Research Misconduct, Bias, and Hype and in the COVID-19 Pandemic.Journal of bioethical inquiry · 2023
   Article
3. SARS-CoV-2: An Updated Review Highlighting Its Evolution and Treatments.Vaccines · 2022
   Review
4. Molecular characteristics, immune evasion, and impact of SARS-CoV-2 variants.Signal transduction and targeted therapy · 2022
   Review
5. Outside any therapeutic trial prescription of hydroxychloroquine for hospitalized patients with covid-19 during the first wave of the pandemic: A national inquiry of prescription patterns among French hospitalists.PloS one · 2022
   Article
6. Is rapid scientific publication also high quality? Bibliometric analysis of highly disseminated COVID-19 research papers.Learned publishing : journal of the Association of Learned and Professional Society Publishers · 2021
   Article
7. Adverse Cardiovascular Effects of Anti-COVID-19 Drugs.Frontiers in pharmacology · 2021
   Review
8. Update on COVID-19: A teleconference with the Paediatric Virology Study Group (Review).Experimental and therapeutic medicine · 2020
   Review
9. A consideration of convalescent plasma and plasma derivatives in the care of Severely-ill patients with COVID-19.Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis · 2020
   Review
10. No small matter: a perspective on nanotechnology-enabled solutions to fight COVID-19.Nanomedicine (London, England) · 2020
    Article
11. [Ethics and biomedical research during the COVID-19 epidemic: Let's not confuse speed and precipitation!]Annales pharmaceutiques francaises · 2020
    Article
12. Targeting the sAC-Dependent cAMP Pool to Prevent SARS-Cov-2 Infection.Cells · 2020
    Review
13. Ethical rationale for better coordination of clinical research on COVID-19.Research ethics · 2020
    Article
14. Studies of Novel Coronavirus Disease 19 (COVID-19) Pandemic: A Global Analysis of Literature.International journal of environmental research and public health · 2020
    Review
15. SARS-CoV-2 COVID-19 susceptibility and lung inflammatory storm by smoking and vaping.Journal of inflammation (London, England) · 2020
    Review
16. Chloroquine and hydroxychloroquine in the management of COVID-19: Much kerfuffle but little evidence.Therapie
    Review

Corrections and comments

• Comment on
  Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.2020
• Comment on
  Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.2020

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as